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Abstract
The henipaviruses, represented by Hendra (HeV) and Nipah (NiV) viruses are highly pathogenic zoonotic paramyxoviruses
with uniquely broad host tropisms responsible for repeated outbreaks in Australia, Southeast Asia, India and Bangladesh.
The high morbidity and mortality rates associated with infection and lack of licensed antiviral therapies make the
henipaviruses a potential biological threat to humans and livestock. Henipavirus entry is initiated by the attachment of the
G envelope glycoprotein to host cell membrane receptors. Previously, henipavirus-neutralizing human monoclonal
antibodies (hmAb) have been isolated using the HeV-G glycoprotein and a human naı¨ve antibody library. One cross-reactive
and receptor-blocking hmAb (m102.4) was recently demonstrated to be an effective post-exposure therapy in two animal
models of NiV and HeV infection, has been used in several people on a compassionate use basis, and is currently in
development for use in humans. Here, we report the crystal structure of the complex of HeV-G with m102.3, an m102.4
derivative, and describe NiV and HeV escape mutants. This structure provides detailed insight into the mechanism of HeV
and NiV neutralization by m102.4, and serves as a blueprint for further optimization of m102.4 as a therapeutic agent and
for the development of entry inhibitors and vaccines.
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Introduction
Henipaviruses, Hendra virus (HeV) and Nipah virus (NiV) [1],
are recently emerged, highly pathogenic paramyxovirus zoonoses
whose major reservoirs in nature are several species of pteropid
fruit bats [2,3]. HeV causes lethal respiratory disease and
encephalitis in horses and severe respiratory disease or late onset
encephalitis in humans. In total, there have now been 39 HeV
spillover events in Australia including 7 cases of human infection
with 4 fatalities since 1994 [4–9]. NiV subsequently emerged in
peninsular Malaysia in 1998–99, causing a large outbreak of
respiratory disease in pigs and encephalitis among pig farmers,
and was later shown to be closely related to HeV [1]. Similar to
HeV, nearly annual outbreaks of NiV infection have been
observed. These NiV outbreaks have been associated with
significantly higher case fatality rates in people, up to 100%,
and several outbreaks have also been linked to the consumption
of raw date palm sap contaminated with virus as well as human-
to-human transmission [10–12]. To date, there have been 570
reported cases of NiV infection in people with 305 fatalities
[8,13,14]. The unusual broad species tropism, high morbidity
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and mortality rates, as well as the lack of any licensed
therapeutics, have rendered the henipaviruses Biological Safety
Level-4 (BSL-4) pathogens and potential biological threats to
humans and livestock.
An often utilized approach to antivirus drug design is to block
viral entry via small molecules, peptides and neutralizing
monoclonal antibodies (mAbs) that bind to the viral surface
glycoproteins. A unique feature of the majority of paramyxoviruses
is that they require two surface glycoproteins for host cell entry: a
Class I fusion (F) glycoprotein and an attachment glycoprotein,
which can be a hemagglutinin–neuraminidase (HN), hemaggluti-
nin (H), or as in the case for henipaviruses a G glycoprotein that
has neither hemagglutinating nor neuraminidase activities [2].
The henipavirus G glycoprotein engages the host cell membrane
protein receptors ephrin-B2 and -B3, and this initial interaction is
believed to be sufficient to trigger the F-mediated fusion event
between the viral envelope and the host cell membrane leading to
virus entry [15,16,17]. In the absence of available vaccines or
antiviral drugs, neutralizing hmAbs offer the possibility for
effective pre- and/or post-exposure treatment for many important
human viral infections. Previously, several hmAbs, m101–m107,
were isolated using a recombinant soluble Hendra virus G (HeV-
G) glycoprotein as the antigen for panning of a large naı¨ve
antibody library [18]. Among the hmAbs, m102 and its derivatives
(m102.1-8) generated by heavy chain random mutations and light
chain shuffling, showed improved binding to HeV-G; clone
m102.4 had equal or higher binding affinity than the other clones
and was selected for further characterization and converted to an
IgG1 format [19]. The m102.4 hmAb was able to cross-react with
both NiV-G and HeV-G in vitro with 50% inhibitory concentra-
tions (IC50)of less than 40 ng/ml and 600 ng/ml for Nipah virus
and Hendra virus, respectively, and is capable of neutralizing all
available isolates of HeV and NiV [19,20]. In animal disease
models, m102.4 has been shown capable of protecting ferrets
against a lethal NiV challenge [20], as well as African green
monkeys (AGM) against a lethal HeV challenge [21,22], in time
frames of 10 to even 72 hours post viral exposure, respectively. In
light of the experimental success of this post-exposure treatment of
both NiV and HeV infection, m102.4 has since been administered
on a compassionate use basis to two individuals in Australia with a
high risk of HeV exposure during the 2010 HeV spillover, and
again in 2012 in another person exposed to HeV. In 2013, m102.4
was used again by compassionate use protocol in an individual
with a laboratory exposure to NiV in United States. In all these
cases, none of these individuals showed symptoms of HeV or NiV
infection at the time of m102.4 administration, and all individuals
remain in good health to date. Altogether, as a fully human mAb,
m102.4 shows promise as a potential prophylactic or therapeutic
agent against henipavirus infection, and appears to be suitable for
controlled safety trials in humans.
To fully characterize the binding epitope [19], as well as the
binding and recognition mechanism, we determined and here
present the crystal structure of the complex between the globular
head domain of HeV-G and the Fab domain of m102.3, a close
derivative of m102.4, featuring an identical heavy chain and a
similar light chain. The structure reveals the molecular mechanism
of neutralization and cross-reactivity and provides a basis for
further improvement of m102.4, including efficacy enhancement
and escape mutant prevention. Additionally, the presented
structural information may aid the development of a henipavirus
vaccine or other specific entry inhibitors.
Results
Structure of the m102.3/HeV-G protein complex
The head domain of HeV-G (residues 171-602) was produced
using the baculovirus expression system, and the Fab domain of
m102.3 was expressed in HB2151 cells. The protein complex was
generated by mixing HeVsG with hmAb in a 1:1.5 molar ratio
followed by a 6 hour incubation and purification by Size-
Exclusion Chromatography (SEC). The peak fractions containing
the complex were collected and used for crystallization.
We obtained two crystal forms of the m102.3/HeV-G complex
and used molecular replacement to determine the structures at
2.7 A˚ resolution (in space group P6122) and at 2.8 A˚ resolution (in
space group I222) (Table S1). There is one 1:1 complex per
asymmetric unit in both crystal forms. The overall structures in the
two crystal forms are very similar (Figure S1) and the region
containing the HeV-G molecules and the complementarity
determining region-3 of the heavy chain (CDR-H3) of the Fabs
can be superimposed with an r.m.s.d of 0.3 A˚ for 386 Ca atoms,
while the two Fab structures, excluding just CDR-H3, can be
superimposed with an r.m.s.d of 0.6 A˚ for 185 Ca atoms. The
difference in the two structures is in the angle between CDR-H3
and the rest of the Fab, which consequentially causes a slight
difference in the buried m102.3/HeV-G interface area: 1070 A˚2
in crystal form I222, and 1010 A˚2 in crystal form P6122. However,
most interface residues in the core region are the same in both
crystal forms. For the remainder of this report and figures, we use
the P6122 structure.
The Fab binds a similar area on HeV-G (Figure 1A) as ephrin-
B2, which is composed of a hydrophobic central cavity and a
hydrophilic rim. Interestingly, CDR-H3 of the Fab approaches the
HeV-G central cavity in a similar angle and from the same direction
as the G-H loop of ephrin-B2 (Figure 1B). The interface involves
Fab residues mostly located on CDR-H3, as well as three CDR-H2
residues (L55, G56 and I57), one CDR-H1 residue (N31) and one
CDR-L1 residue (R30) (Figure 1). The long protruding CDR-H3
(23 residues) adopts a b-hairpin conformation, including a stalk and
a tip (Q105-Y112). The central hydrophobic HeV-G/Fab contacts
Author Summary
Since their initial emergence, henipaviruses have contin-
ued to cause spillover events in both human and livestock
populations, posing significant biothreats. Currently there
are no licensed or approved therapies for treatment of
henipavirus infection and the human case mortality rates
average .70%. We used X-ray crystallography to deter-
mine the high-resolution structures of the Hendra virus G
glycoprotein in complex with a cross-reactive neutralizing
human monoclonal antibody. The structures provide
detailed insight into the mechanism of HeV and NiV
neutralization by this potent and clinically-relevant human
monoclonal antibody that is currently in development for
use in humans. This monoclonal antibody was recently
shown to be an effective post-exposure therapy in non-
human models of lethal Hendra virus infection. Indeed, it
has already been used in four people on a compassionate
use request, three in Australia and one in the United
States, as a therapeutic agent. Furthermore, we identified
and characterized two escape mutants generated in vitro
and evaluated their mechanism of escape. Our results
serve as a blueprint for further optimization of this
antibody and for the development of novel entry
inhibitors and vaccines. This report also supports the
additional pre-clinical data required for eventual licensure
by detailing the antibody’s mechanism of henipavirus
neutralization.
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are formed by embedding the tip of CDR-H3 into the hydrophobic
HeV-G receptor-binding cavity. A simulated annealing omit
electron density map of this region is illustrated in Figure S2.
Among the eight residues on the tip of CDR-H3, L105 is
surrounded by Q559, A532, N557, Y581, I580, I588 and E579 of
HeV-G; P107 is surrounded by T530, A532, P488, T507, Q490 of
HeV-G; P109 is surrounded by E505, W504, Y458 of HeV-G; S110
is surrounded by L305 and W504 of HeV-G; and Y122 is
surrounded by T241, C240, T218, S239 and E579 of HeV-G
(Figure 1A and 2C). In addition, the side chain of Q111, H108 and
P109 of the Fab are stacked together, with Q111, which forms the
top layer of the stack and hydrogen bonds to Q490 of HeV-G. The
surrounding hydrophilic HeV-G/Fab contacts involve residues on
CDR-H3, CDR-L1 and CDR-H2. Notably, R30 on CDR-L1
forms salt-bridges with E533 and D555 of HeV-G; Hydrogen bonds
are also formed between N31 on CDR-H1 and E213 of HeV-G, as
well as between R102, E103, Y112, Y113 and Y114 on CDR-H3
and Y581, S239, T218, Q490 and T241 of HeV-G, respectively
(Figure 1A). All HeV-G residues engaged by m102.3 are listed in
Figure S7. Interestingly, Fab binding does not induce any significant
conformational changes in HeV-G and the r.m.s.d in Ca positions
between unbound and Fab-bound HeV-G is 0.257 A˚. Some
previously identified HeV-G mutations that were reported to affect
the m102 or m102.4 binding [18,19] are not part of the m102.3
epitope (Figure S3) suggesting that those mutations might affect the
overall HeV-G structure.
Hetero-tetrameric packing of the m102.3/HeV-G complex
The HeV-G head domain and Fab are both strictly monomeric,
but, interestingly, when these two proteins are mixed together,
they first form a hetero-dimeric complex that oligomerizes further
in solution. Indeed the SEC assays indicate that 72 hours after
mixing more than 90% of the complex migrates at a position
corresponding to twice its original size in the gel-filtration column.
An explanation of this phenomenon is provided by the crystal
packing of the complex, where two copies of Fab and HeV-G
assemble into a heterotetramer (Figure S4). It should be noted that
the same 2:2 heterotetrameric Fab/HeV-G complex assembly is
observed in both crystal forms. As illustrated in Figure S2, the
heterotetrameric m102.3/HeV-G assembly is generated by a
two-fold crystallographic symmetry axis in which the two Fab
molecules contact each other burying approximately 770 A˚2
Figure 1. Structure of the m102.3/HeV-G complex, and comparison to the ephrin-B2/HeV-G structure. A. Left: Overall Structure of the
m102.3/HeV-G complex viewed from the side. CDR-H3 (magenta) of m102.3 inserts into the central cavity of HeV-G (green). Disulfide bonds are
shown as yellow sticks. The five glycosylation sites of HeV-G are shown as grey spheres. Right: A close up view of the HeVG/m102.3 complex interface.
Residues involved in the interaction are shown as stick figures and labeled. The solvent accessible surface of HeV-G central cavity region, viewed from
top, is presented on the bottom. CDR-H3 residues (magenta) and R30 (cyan, on the light chain of Fab) and their contacting residues on HeV-G (green)
are shown and labeled. B. Overall structure of the ephrin-B2 (orange)/HeV-G (blue) complex. HeV-G in the complex is in the same orientation as in
panel A.
doi:10.1371/journal.ppat.1003684.g001
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surface area on each side, while the two HeV-G molecules
remain separate. Importantly, there is an additional contact area
between the Fab light chains elbow region and the HeV-G
molecule of the interacting complex, in which a further ,240 A˚2
are buried in each binding partner (Figure 2A, blue region).
Thus, a total 1015 A˚2 surface area is occluded on each side of the
interface between the two 1:1 complexes. Within the 2:2
heterotetrameric complex, m102.3 and HeV-G form a more
extensive interacting interface, rendering a more stable assembly.
As shown in Figs. 2A and 2B, the total HeV-G surface region
involved in the HeV-G/m102.3 interaction is almost the same as
the one in the HeV-G/ephrin-B2, B3 interaction. However, the
physiological relevance of this tetrameric assembly, and resulting
cross-linking of mAb/G complexes on the viral membrane, needs
to be studied further.
Comparison of the HeV-G/m102.3 and HeV-G/ephrin-B2
complexes
Ephrin-B2 and m102.3 both interact with the receptor-binding
surface of HeV-G, which includes a central hydrophobic cavity
and surrounding hydrophilic rim. CDR-H3 of m102.3 resembles
the G-H loop of ephrin-B2 in both its shape and the insertion
angle into the HeV-G cavity (Figure 1). Most of the G-H loop-
contacting residues of HeV-G also participate in the CDR-H3
binding (Figure 2 C, D). Unlike ephrin, the binding of m102.3
does not cause any significant conformational changes in HeV-G.
Interestingly, although the tips of the G-H loop and CDR-H3 both
target the pockets in the HeV-G central cavity, each of them uses
slightly different residues and anchoring strategies. As shown in
Figure 2D, from left to right, F117, P119, L121 and W122 on the
ephrin G-H loop insert into four hydrophobic HeV-G pockets,
occupying half of the HeV-G cavity; while L105, P107 and P109
on the m102.3 CDR-H3 insert into the first three of these same
pockets (Figure 2C). Among these, ephrin P119 and P107 of
CDR-H3 are strikingly similar. Additionally, the insertion of
CDR-H3 further embeds S110 and Y112 into the other half of the
HeV-G cavity. The side chain of H108 of CDR-H3 extends in the
same direction as W122 of the G-H loop but does not reach the
fourth pocket. Instead, it is embedded in a groove defined by
Q490, W504, and E505 of HeV-G. A hydrogen bond between
Q111 of CDR-H3 and Q490 of HeV-G further locks the H108 in
this position, preventing the withdrawal of CDR-H3 from the
binding cavity. Since the S110 contacting resides on HeV-G are
L305 and W504, mutation of S110 to A or V could presumably
enhance the interaction between m102.3 and HeV-G. In
summary, CDR-H3 binds to HeV-G utilizing a very high affinity
lock-and-key mode without inducing conformational changes in
HeV-G.
Figure 2. Comparison of the binding interfaces in the HeV-G/m102.3 and the HeV-G/ephrin-B2 complexes. A: The solvent accessible
surface of the HeV-G molecule in the HeV-G/m102.3 complex viewed from the top. HeV-G is colored in green, except for the m102.3-contacting
region that is colored in red (for the 1:1 complex interface) and in blue (for the region contacted by another copy of the light chain in the hetero-
tetrameric 2:2 complex interface). B: The solvent accessible surface view of the HeV-G molecule in the HeV-G/ephrin-B2 complex viewed from the top.
HeV-G is colored in grey, except for the ephrin-B2 contacting region, which is colored in red. C: The tip of the m102.3 CDR-H3 region (in magenta)
bound in the HeV-G surface cavity (in green). D: The tip of the ephrin-B2 G-H loop (in yellow) bound in the HeV-G surface cavity (in grey).
doi:10.1371/journal.ppat.1003684.g002
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Comparison of m102.3 binding to NiV-G and HeV-G
Although m102 mAb was originally isolated against HeV-G, it
demonstrated a more potent neutralization capacity against NiV
than HeV. Indeed, in vitro binding measurements using BioLayer
Infetrometry (Table S2) document that both m102.3 and m102.4
display higher binding affinities for NiV-G than for HeV-G. Due to
the high similarity between NiV-G and HeV-G, presumably
m102.3 binds to NiV-G and HeV-G in a very similar manner,
but an examination of the structure highlights some small structural
differences that may explain the increased affinity of m102 for NiV-
G. Upon superimposition of NiV-G to the m102.3-bound HeV-G,
we found that only three residues at the mAb contacting regions are
different. Among them, T507 and Y458 in HeV-G, which are part
of the binding pockets for P107 and P109 of CDR-H3, are replaced
by two hydrophobic residues, Valine and Phenylalanine, in NiV-G
(Figure 3). Increasing hydrophobicity in this area very likely
strengthens the predominantly hydrophobic interaction between
the G protein and m102.3, enhancing its neutralizing activity.
m102.3 vs. m102.4
The panel of m102 derivatives was generated by light chain
shuffling and heavy chain random mutagenesis. Among them,
m102.4 was reported to have an equal or slightly higher affinity to
henipavirus G glycoproteins in comparison to the others [19].
BioLayer Interferometry (Table S2), on the other hand indicates
that m102.3 actually has slightly higher binding affinities to both
NiV-G (KD: 5.6 nM) and HeV-G (KD: 27.4 nM) than m102.4
(KD: 25.5 nM and 111 nM, respectively). The primary sequences
of m102.4 and m102.3 are overall highly similar, featuring an
identical heavy chain (which provides all but one of the binding
residues) and 15 different light chain amino acid that are not part
of the m102.3/HeV-G interface (Figure S6) (but indirectly account
for the small differences in binding affinities). As all HeV-G
contacting residues in m102.3 are conserved in m102.4, the
structural information obtained from the m102.3/HeV-G com-
plex could also be applied to explain the mechanism of m102.4
neutralization. In the neutralization assay we performed, the
efficiency of the m102.4 mAb to wild type NiV and HeV is three
folds higher than that of the m102.3 Fab and m102.4 Fab,
highlighting the importance of dimerization conferred by the Fc
region. Notably, the efficiency of the m102.3 Fab is within the
same range or slightly lower than that of the m102.4 Fab (Figure 4),
suggesting that the neutralization efficiency may also be affected
by the other factors, such as protein stability or flexibility.
Generation of virus escape mutants
To further detail and characterize the binding of the hmAb to
the virus, infectious NiV and HeV were used to generate antibody
Figure 3. Comparison of the m102.3-binding regions of HeV-G and NiV-G. The HeV-G (green) and NiV-G (purple) structures are
superimposed and viewed from top. The m102.3 contacting residues of HeV-G and the corresponding residues of NiV-G are shown and labeled. Most
residues are conserved between HeV-G and NiV-G except for three: T/S241, T/V507 and Y/F458.
doi:10.1371/journal.ppat.1003684.g003
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neutralization escape mutants by incubating and culturing high
titers of virus in the presence of hmAbs m102.3 (Fab fragment) or
m102.4 (Fab fragment and mAb). After 3 passages, the resulting
virus stocks were plaque purified and tested for neutralization
efficacy. The G and F glycoprotein genes from a minimum of five
plaques of each escape variant were sequenced in order to identify
mutations associated with the antibody escape phenotype. For the
NiV escape mutant, all ten plaques of both the m102.3 and
m102.4 escape mutants contained a single amino acid change at
location V507I. HeV mutants that escaped m102.4 neutralization
all contained a single amino acid mutation at location D582N
(Figure S5). The m102.3 and m102.4 cloned virus stocks of these
escape mutants of NiV and HeV, in contrast to wild-type NiV and
HeV, were no longer neutralized by m102.4 at antibody
concentrations exceeding 100 mg/ml (Figure 4). In addition, the
cloned virus stocks of the escape mutants were then analyzed in
single round growth assays in comparison to wild-type HeV and
NiV on Vero E6, HeLa-USU-ephrin-B2 and HeLa-USU-ephrin-
B3 cells (Figure 5). Both neutralization escape mutants grew as
efficiently and to equal titers as the wild-type virus in Vero E6
cells. Noticeably however, during passaging, the m102.3 and
m102.4 neutralization resistant viruses were relatively slow in
developing cytopathic effects (CPE). Whole genome sequence was
performed to identify any additional mutations in these two
escapes, as compared to their parent strains (sequencing report is
attached in Supporting Materials as Report S1). The HeV escape
variant contains another silent mutation in the P gene, in addition
to the D582N mutation in the G gene; while the NiV escape
variant contains mutations in the N gene (39 end), M gene and L
gene, in addition to the V507I mutation in the G gene. Thus, the
escape is certainly due to the mutation in the G gene in case of the
D582N HeV escape mutant.
Whole genome analysis of the parent virus stocks and the escape
mutants and identification of all SNPs, indicates that the likely
reason for the slow appearance of CPE in the presence of m102.4
was the need for resistant virus amplification to levels sufficient for
cell-cell fusion.
Combined with binding affinity measurements (Table S2), the
HeV-G/m102.3 structure provides clues to the escape mecha-
nism of the escape mutants (Figure 2C and D). Interestingly, the
affinity of the G proteins to both antibodies and ephrin-B2 was
increased by the V507I mutation in NiV-G, and decreased by the
D582N mutation in HeV-G. Residue V507I is located at the
bottom of the NiV-G cavity, interacting with P119 of ephrin-B2,
B3 and P107 of m102.3. The additional methyl group of I507
would likely result in a more intimate interaction with both the
CDR-H3 and G-H loops resulting in a lower KD value due to a
decreased dissociation (koff) rate. Furthermore, ephrinB2 binding
benefits slightly more than both antibodies from the V507I
substitution. Intriguingly, D582 is located on the B6S2-S3 loop of
the G protein, which is outside of the receptor/mAb binding
region, suggesting the D582N mutation affects the Fab/G-protein
interaction through an indirect pathway (Figure S5). D582 forms
salt-bridges with two residues on B6S3, R589 and K591. The
D582N mutation would likely cause a conformational change in
B6S3, causing re-arrangement of several m102.3-contacting
residues including I580, Y581 and I588, thus hindering the
insertion with both the CDR-H3 and G-H loops. Indeed, the
observed association rates (kon, Table S2) of this mutant to both
antibodies and ephrinB2 decreased similarly. However, such a
conformational change would affect the overall ephrin binding
less, and it seems a similar rearrangement takes place even in the
wild-type G protein (Figure S5) [9,23]. Indeed, I580, Y581 and
I588 are the pocket-forming residues for F117 of ephrinB2
(Figure 2D). The elimination of the two salt-bridges resulting
from the D582N substitution might even have a slight stabilizing
effect on the G-H loop insertion. Accordingly, the observed
dissociation rate (koff) for binding of the HeV-G mutant (D582N)
Figure 4. Neutralization efficacy of wild-type and neutralization-escape mutants by m102.4 mAb, m102.4 Fab and m102.3 Fab.
Wild-type (WT) Nipah (NiV) and Hendra (HeV) viruses and their respective m102.4 neutralization escape mutants NiV-V507I and HeV-D582N were used
to evaluate the neutralization efficacy of m102.4 mAb, m102.4 Fab and m102.3 Fab. Starting concentration of m102.4 was 100 mg/mL. The mAb and
Fab concentrations at which 50% of the virus was neutralized are plotted. Error bars represent standard deviations. * t-test; p,0.001 compared to WT.
doi:10.1371/journal.ppat.1003684.g004
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to ephrin-B2 was slightly decreased, while the dissociation rates
for binding the antibodies were increased. In summary, both
mutations in the G protein favor ephrin-B2 binding as compared
to mAb binding, consistent with their neutralization-escape
phenotypes.
Discussion
Targeting the viral surface spike proteins has been a powerful
strategy in the development of neutralizing mAbs. Similar to m102
targeting the henipavirus G proteins, a number of potent
antibodies have been developed against the spike (S) glycoprotein
of the SARS-associated coronavirus, the hemagglutinin glycopro-
tein of influenza virus and the envelope glycoprotein of HIV. The
epitopes recognized by these antibodies are often functionally
associated with the viral entry mechanism (e.g. attachment and
membrane fusion) to reduce the occurrence of escape mutants. For
instance in HIV, the epitopes targeted by neutralizing antibodies
are located in four regions: receptor binding site (RBS), fusion
associated membrane-proximal external region (MPER) region,
conserved glycan structures and glycan associated loop regions,
while in influenza, the epitopes are located in the fusion associated
stem region and sialic acid binding pocket region [24–26]. In
henipaviruses, as in all members of the paramyxovirus family, the
attachment and fusion functions are exerted by two different
proteins, which renders as possible epitope locations the RBS, the
fusion-related regions, and sites associated with transducing the
fusion-triggering signal from the attachment to the fusion proteins.
In the past years, crystal structures of complexes between viral
RBS and neutralizing antibodies have been determined, including
m396 and 80R targeting the SARS S glycoprotein RBS [27,28],
CH65 and C05 targeting the influenza virus sialic acid binding
pocket [24,29], and b12, HJ16, VRC01, NIH45-46, 12A12,
3BNC117, VRC-PG04 and VRC-CH31 targeting the HIV-1
CD4-binding site (reviewed in [26]). Interestingly, in many of the
examples above, the antibody CDR region mimics the conforma-
tion of the binding region of the cellular receptor (either protein or
carbohydrate). Amongst them, most similar to our m102.3/HeV-
G structure are the structures of CH65 and C05 targeting the
influenza virus sialic acid binding site, which is a conserved
shallow groove. All three mAbs use only CDRH3 to bind their
target groove, but compared to CH65, C05 contacts a larger
conserved region in the RBS, without interacting with the
surrounding variable regions, which accounts for its greater
neutralization breadth. The same strategy could be applied to
further improve m102.3/4.
The m102.3/4 antibodies feature a long CDR-H3 (23 residues
in kabat numbering), adapting a b-hairpin, providing an
interesting example of how antibodies circumvent obstacles in
reaching the targeted epitope. One of the challenges in viral
epitope targeting is that the epitopes are sometimes hidden, either
behind heavy glycosylation or deep in a cavity. Another example
of a long CDR-H3 forming a b-hairpin is the antibody 2909
against HIV (21 residues) [30]. The extreme cases in this category
are the HIV neutralizing antibodies PG9 and PG16, which
contain a 28-residue axe-shaped CDR-H3 [31,32].
Of the many tested therapeutic strategies to prevent and/or
treat infection and disease caused by the henipaviruses in a variety
of well-characterized animal models, few have been effective
[33,34]. Recently, the only post-exposure therapeutic option that
is highly effective in animal models with clear potential for future
approved human use applications has been the hmAb m102.4
[20,21]. The reported success of m102.4 in a nonhuman primate
model of HeV infection has been particularly encouraging, and
the m102.4 exhibited an excellent distribution half-time (,1 day)
and elimination half-time (,11 days) in the AGM. No evidence of
HeV-specific pathology was observed in any of the m102.4-treated
animals and no infectious HeV could be recovered. This study
revealed that hmAb m102.4 prevented wide-spread HeV dissem-
ination in virus challenged subjects, and was the first successful
Figure 5. In vitro growth characteristics of wild type NiV and
HeV and m102.4 neutralization escape mutants NiV-V507I and
HeV-D582N. Cultures of (A) Vero E6, (B) HeLa-USU cells expressing
human ephrin-B2 (HeLa-ephrin-B2) or (C) human ephrin-B3 (HeLa-
eprhin-B3) were infected in triplicate with wild type and m102.4
neutralization escape mutants at a multiplicity of infection of 1 as
described in Materials and Methods. Virus titers at different time points
were determined by TCID50 using Vero E6 cells. Solid black line, NiV;
solid grey line, NiV-V507I; dotted black line, HeV; dotted grey line, HeV-
D582N. Error bars represent standard deviations.
doi:10.1371/journal.ppat.1003684.g005
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post-exposure in vivo therapy against HeV and the first in a
nonhuman primate [21]. During the 2010 HeV spillover
occurrence in Queensland, Australia, there were two individuals
that were considered to be at high risk of HeV infection [35]. The
m102.4 hmAb was requested by Australian health authorities and
administered to the two individuals as a compassionate use
therapeutic option even though no human safety testing has been
carried out and it was not recommended for use in humans. In this
instance, m102.4 was administered to the individuals prior to any
HeV diagnosis or onset of clinical disease [35] with doses
(,19 mg/kg) sufficient to achieve a high serum concentration,
and to date both individuals remain healthy and no evidence of
HeV infection has been reported. The antibody appeared well
tolerated when administered which was not unexpected since
m102.4 is a human mAb. The m102.4 hmAb is now in further
pre-clinical development stages in both the United States and
Australia.
As part of our continued characterization of m102.4 we sought
to provide the molecular details of its ephrin receptor blocking
activity by determining the crystal structure of a (nearly identical)
m102.4 derivative, m102.3, which possesses the same cross-
reactive neutralizing and henipavirus G binding activity with an
identical heavy chain sequence and G glycoprotein binding loop in
the CDR3 domain. The structure reported here of the HeV-G/
m102.3 complex reveals the molecular mechanism underling the
exceptional cross-reactivity and neutralizing potency of these
antibodies. The binding of the hmAb to the G glycoprotein
involves a single loop of its heavy chain with hydrophobic amino
acid residues occupying the same pockets in G that the ephrin
receptors engage during receptor binding. It is clear now that the
central cavity on the henipavirus G glycoprotein receptor-binding
face is vital for viral attachment and infection. From the crystal
structure of the m102.3/G protein complex, we know that
blocking access to this cavity is a feasible and efficient way of
inhibiting henipavirus attachment and infection. Specific peptide
or small-molecule inhibitors for the viral attachment glycoprotein
can be designed based on the structural data. For example, the
existing pockets in the G glycoprotein cavity can be used as targets
in structure-based computational screens. Another approach
would be to screen compound libraries using a protein interaction
primary assay, and then optimize the initial hits to better fit the
binding cavity.
The data presented here are consistent with the initial steps of
the henipavirus entry models proposed earlier based on the
analysis of the G glycoprotein and the ephrin receptor/G
glycoprotein complex structures [23,36–38]. Of further impor-
tance, the new hmAb 102.3/G complex structure provides
important information and leads for potential antibody improve-
ment in two regards: increasing the antibody’s affinity to the G
glycoprotein in order to obtain even higher efficiency, and
manipulating the interacting interface in order to reduce the
potential of occurrence of escape mutants. The difficulty of the
second aspect lies in the observation that the affinity of the
attachment proteins to their receptors is not strictly correlated with
the infection efficiency of henipaviruses. Thus, mutations that
affect the henipavirus G glycoprotein binding affinities to ephrin
receptors and mAbs to similar degrees could still allow potential
escape. We indeed observed that even though there was a
remarkable overlap between the m102.3 epitope and the receptor
binding region of henipavirus G, two escape mutant variants of
HeV and NiV, containing G glycoprotein mutations D582N and
V507I respectively, were identified. In vitro manipulation, such as
repeated passaging of virus and allowing replication in the
presence of a neutralizing antibody is routinely used as an
approach to generate escape variants that can then be examined as
a means to map epitopes and detail mAb neutralization
mechanisms. However, it should be emphasized that the
appearance of m102.4 escape variants has not been observed in
any of the in vivo efficacy testing against HeV or NiV to date, and
this is likely explained by the fact that very high doses of mAb are
utilized, similar to mAb dosing used in people in the prophylactic
treatment of RSV infection with F (Synagis/Palivizumab) [39]. In
addition, the effectiveness of m102.4 appears to be by virtue of its
ability to slow the progression and dissemination of virus within
the challenged host, allowing the host an effective window in
which to mount its own innate and adaptive immune response that
eventually prevents lethal disease outcome.
Taken together, the success of hmAb m102.4 in vivo as an
effective post-exposure treatment against henipavirus disease in
two different well-characterized animal models (the ferret and
nonhuman primate), along with the new detailed structural
findings on its viral G glycoprotein binding features that help
explain its superior cross-reactive neutralizing activity, will
facilitate efforts aimed at obtaining approved human use
application to treat accidental exposure to HeV or NiV infection.
Materials and Methods
Protein expression and purification
Soluble head domain (amino acid residues 171-602) of HeV-G
was cloned into a pGP67 vector and expressed in the Baculovirus
expression system (BD Biosciences). The plasmid was transfected
into SF9 cells using Cellfectin (Invitrogen) and Baculo-Gold
linearized Baculovirus DNA (BD Biosciences). The virus was then
amplified in SF9 cells for three rounds to reach the proper titer
before applying to Hi5 cells for final expression (in 1:100 volume
infection ratio). The infected Hi5 cells were harvested 48 hours
after infection. The cell media containing the HeV-G protein was
purified using ion-exchange and size-exclusion chromatography
(GE Biosciences). Soluble Fab was expressed and purified as
described [18,19]. The HeV-G/m102.3 complex was obtained by
mixing the two proteins in a 1:1.5 molar ratio and was passed
through a Superdex 200 column (GE Biosciences). The fractions
containing both proteins were collected and concentrated to
10 mg/ml in HBS buffer (20 mM Hepes pH 7.2, 10 mM KCl).
Crystallization and structure determination
The initial crystallization condition was obtained with Wizard
III (Emerald Biosystems) and Pro-complex (Qiagen) screens using
robot screening (TTP LabTech’s Mosquito). After several rounds
of optimization using hanging drop vapor diffusion at room
temperature, two crystals forms were obtained in conditions: 17%
PEG 3350, 0.18M (NH4)3Citrate, and 15% PEG4000, 0.1M
Hepes pH 7.0, 0.1M MgCl2. Crystals were frozen in liquid
Nitrogen with 20% glycerol as cryo-protectant. Diffraction data
were collected at beamline NE-CAT ID-24 of the Advanced
Photon Source at Argonne National Laboratory. Data images
were processed using program HKL2000. The structures were
determined by molecular replacement with PDB ID 3D11 (NiV-
G) and 1RZ1 (hmAb against GP120 of HIV virus). Phaser [40],
COOT [41] and PHENIX REFINE in the program suite
PHENIX [42] were used for structure determination, model
building and refinement. The details of the crystallographic
analysis are presented in Table S1.
Escape mutant analysis
Neutralization resistant NiV and HeV mutants were generated
by incubating 16105 TCID50 of each virus with 100 mg or 10 mg
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of mAbs m102.3 (NiV) and m102.4 (NiV or HeV) respectively, in
100 ml media for 1 h at 37uC and then inoculated onto 106 Vero
E6 cells in the presence of mAbs at the same concentration. The
development of cytopathic effect (CPE) was monitored over 72 h
and progeny viruses harvested. MAb treatment was repeated two
additional times with CPE developing slowly with each passage.
Passage 3 viruses were plaque purified in the presence of mAbs
and neutralization resistant viruses were isolated. Experiments
were performed in duplicate and the glycoprotein and fusion
protein genes of individual plaques from each experiment were
sequenced. The neutralization titers between wild type and the
neutralization resistant virus were determined by micro neutral-
ization assay. Briefly mAb m102.4 and Fabs m102.3 and m102.4
were serially diluted two-fold, and incubated with 100 TCID50 of
the wild type (WT) and neutralization resistant NiV or HeV for
1 h at 37uC. Virus and antibodies were then added to a 96-well
plate with 26104 Vero E6/well in 4 wells per antibody dilution.
Wells were checked for CPE 3 days post infection and the 50%
neutralization titer was determined as the mAb concentration at
which at least 50% of wells showed no CPE.
Virus growth curves
Growth curves were performed by inoculating cell cultures with
NiV, HeV and their escape mutants at a multiplicity of infection
(MOI) of 1 for 1 h, after which the cells were washed 3 times with
PBS and overlaid with medium. Virus samples were obtained at
various time points after infection and stored at 280uC until viral
titers were determined by TCID50.
Binding-affinity measurements
The binding kinetics of the wild type or mutant G proteins to
both antibodies (m102.3 and m102.4) or to ephrin-B2 were
measured by bio-layer interferometry on a BLItz instrument
(ForteBio). Ni-NTA biosensors were used to immobilize the hexa-
Histidine fused antibodies and ephrin-B2 proteins. Kinetic
parameters (kon and koff) and affinities (KD) were calculated from
a non-linear fit of the BLItz instrument data using the BLItz
software.
Whole genome sequencing and analysis
250 mL of each virus was mixed with 750 mL Trizol LS and
RNA was extracted following the manufacturers guidelines.
Illumina TruSeq cDNA libraries were prepared from total
RNA, omitting the polyA selection step. Each library was
subjected to half a MiSeq run using a 300 cycle kit, paired end
sequencing. A quality control tool for high throughput sequence,
FASTQC, a java stand-alone program was downloaded from
Babraham Bioinformatics Institute: http://www.bioinformatics.
babraham.ac.uk/projects/fastqc/ and each fastq file was checked
for quality. Resulting WT HeV and WT NiV reads were mapped
to their respective reference genomes, NC_001906 and
NC_002728, using CLC Genomics Workbench v6.0.4, using
default parameters. Consensus sequence was extracted for each
and used as the reference genome to which the reads resulting
from sequencing the mutant samples were mapped. Consensus
sequence for each mutant was extracted and aligned to the WT
using CLC Genomics Workbench v6.0.4, and default parameters.
Sequences alignment
Henipavirus G attachment glycoprotein sequences were aligned
in CLC Main Workbench v5.7.1 using default parameters (gap
open cost = 10; gap extension cost = 1).
Illustrations
All molecular representations were produced with PyMOL
(Delano Scientific LLC). Figures were prepared using Adobe
Illustrator, Adobe Photoshop.
Supporting Information
Figure S1 Comparison of the Fab/HeV-G structures in
the two crystal forms. A: The m102.3/HeV-G complex
structures in the two crystal forms were superimposed using the
Fab as a reference. B: The complex structures were superimposed
using HeV-G as a reference. Fab and HeV-G are colored in blue
and grey in the P6122 crystal form, and magenta and lime in the
I222 crystal form, respectively.
(TIF)
Figure S2 Electron density map at the m102.3 CDR-H3/
HeV-G interface. The interface between m102.3 CDR-H3
(magenta) and HeV-G (green) is illustrated. The contacting
residues are labeled and shown in stick. The simulated annealing
omit electron density map of the tip region of the m102.3 CDR-
H3 is shown as blue mesh (contour level 3s).
(TIF)
Figure S3 Mapping previously identified HeV-G muta-
tions that affect antibody binding. The locations of all
previously reported mutants are shown using the m102.3/HeV-G
complex structure. Those affecting m102 binding are color in red,
while those affecting m102.4 binding are colored in yellow. None
of the residues are in direct contact with m102.3.
(TIF)
Figure S4 Hetero-tetrameric packing of the m102.3/
HeV-G complex. The two HeV-G molecules (green) in the
tetramer are connected by two Fab molecules. Fab1 (magenta
heavy chain and cyan light chain) mainly binds to the HeV-G
molecule that is on the bottom of the left panel and on the left side
of the right panel. Fab2 (red heavy chain and blue light chain)
mainly binds to the HeV-G molecule that is on the top of the left
panel and on the right side of the right panel.
(TIF)
Figure S5 Mechanism of the D582N m102.3/m102.4
escape mutant. The m102.3/HeV-G complex viewed from the
side around the B6 region of HeV-G. The HeV-G molecule is
colored in green and the m102.3 molecule is colored in magenta.
The HeV-G molecules in the ephrin-B2 bound state (grey) are
superimposed with the m102.3 bound HeV-G molecule. D582
forms salt-bridges with R589 and K591 in both unbound and
m102.3-bound HeV-G, but not when the molecule is bound to
ephrin-B2. D582 of unbound and ephrin-B2-bound HeV-G is
shown in thin stick. The B6S2-S3 loop of ephrin-B2-bound HeV-
G sterically crashes with CDR-H3 of m102.3 upon superimpo-
sition of the HeV-Gs.
(TIF)
Figure S6 Amino acid sequences alignment between
m102.3 and m102.4. The G-protein binding residues are
highlighted in red. CDR-1, -2 and -3 of both the heavy and light
chains are highlighted in blue.
(TIF)
Figure S7 Amino acid sequences alignment between
HeV-G and NiV-G. The primary sequences of the HeV and
NiV G proteins are aligned. The G glycoprotein residues
interacting with mAb 102.3 (the epitope residues) are highlighted
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in red. These residues are conserved in all virus isolates reported in
Genebank.
(TIF)
Report S1 Henipavirus antibody escape sequencing
report.
(PDF)
Report S2 Alignment of G proteins in all reported
Hendra virus isolates in Genebank.
(PDF)
Report S3 Alignment of G proteins in all reported Nipah
virus isolates in Genebank.
(PDF)
Table S1 Crystallographic data and refinement statis-
tics.
(DOC)
Table S2 Affinity measurements of the mAb/G and
ephrin-B2/G interactions performed using BioLayer
Interferometry. EFNb2 is ephrin-B2. A bar graph of the
measured KD values is also provided.
(DOC)
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